Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01027897 · ClinicalTrials.gov registry record · Phase 4
Pharmacokinetic and Pharmacodynamic Evaluation of Doripenem in Critically Ill Trauma Patients
A Phase 4 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT01027897 is a Phase 4 study that has completed, run by Emory University. The registered enrollment target is 30 participants.
The verdict
NCT01027897, a Phase 4 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
The study hypothesis is to measure how the drug doripenem is cleared from the body of critically ill trauma patients. The investigators will measure blood drug concentrations and calculate how much the drug distributes in the body and how fast it is removed from the body. There is little information on how drugs are cleared in critically ill patients and the wrong dose of a drug could make it ineffective. The investigators will use this information to predict the most reasonable dose to treat infections effectively in these patients.
Interventions
- DRUG Doripenem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2010-04 |
| Est. Completion | 2011-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01027897
The ClinicalTrials.gov registry entry for NCT01027897 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Doripenem is the first listed.
NCT01027897 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01027897 about?
NCT01027897 is a clinical study titled "Pharmacokinetic and Pharmacodynamic Evaluation of Doripenem in Critically Ill Trauma Patients". The study hypothesis is to measure how the drug doripenem is cleared from the body of critically ill trauma patients. The investigators will measure blood drug concentrations and calculate how much the drug distributes in the body and how fast it is removed from the body. There is little information...
What is the current status of trial NCT01027897?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2010-04. Estimated completion is 2011-12.
What interventions are being tested in trial NCT01027897?
The interventions under investigation include: Doripenem (DRUG).
Who is sponsoring clinical trial NCT01027897?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.